Devonian Health Group Inc. announced that it has formed a Scientific Advisory Board comprised of experts in botany, chemistry, immunology, infectious diseases, drug discovery and development. This Scientific Advisory Board will assist Devonian’s Research and Development team in the development of cannabinoïds-based pharmaceutical drugs. The appointees are Dr. Louis Flamand, PhD, MBA (Laval University), Dr. Suha Jabaji, PhD (McGill University), Prof. Francois Malouin, PhD (Université de Sherbrooke), and Dr. John Trant, PhD (University of Windsor). Louis Flamand, PhD, MBA, is a full professor and chair of the department of microbiology-infectious-disease-immunology at the Faculty of medicine, Université Laval and senior researcher in the division of infectious and immune diseases at the CHU de Quebec research center-Université Laval. Dr. Suha Jabaji, PhD. is a molecular plant pathologist in training. She obtained her PhD from the University of Waterloo, Ontario, Canada. At the rank of full Professor in Plant Science, McGill University, her scientific contributions are recognized at the national and international levels. François Malouin is professor (microbiology) at the Department of biology at the Faculty of sciences of Universite de Sherbrooke since 2000. Dr. John Trant received his PhD from the University of Ottawa in 2012 in making antifreeze glycopeptides under the supervision of Dr. Robert Ben. After postdoctoral work with Dr. Tomas Hudlicky (natural product synthesis, Brock) and Dr. Elizabeth Gillies (polymer and nanoscience, Western) he began his own group at the University of Windsor in 2016.